newsfilter
← Latest News
ACCESS Newswire·

Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients

Despite Primary Endpoint not Being Met, Due to Small Sample Size, Results Show a Very Positive Trend in Efficacy Parameters with a Clean Safety and Tolerability Profile GENEVA, SWITZERLAND / ACCESSWIRE / March 17, 2022 / RELIEF THERAPEUTICS Holding SA (